ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Study Protocol
Revised

Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC)

[version 2; peer review: 5 approved]
* Equal contributors
PUBLISHED 16 Sep 2016
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Current standard-of-care tumor sampling protocols for CCRCC (and other cancers) are not efficient at detecting intratumoural heterogeneity (ITH). We have demonstrated in silico that an alternative protocol, multi-site tumor sampling (MSTS) based upon the divide and conquer (DAC) algorithm, can significantly increase the efficiency of ITH detection without extra costs. Now we test this protocol on routine hematoxylin-eosin (HE) sections in a series of 38 CCRCC cases. MSTS was found to outperform traditional sampling when detecting either high grade (p=0.0136) or granular/eosinophilic cells (p=0.0114). We therefore propose that MSTS should be used in routine clinical practice.

Keywords

Intratumor heterogeneity, tumor sampling, multi-site tumor sampling grade, pathology, clear cell renal cell carcinoma

Revised Amendments from Version 1

The authors thank all the comments and suggestions of the referees. A mention of what is really the divide and conquer strategy has been included in the Introduction. The Material and Methods section also includes additional information related to the amount of tissue evaluated in both protocols and the way we did it. Finally, a new paragraph (with an additional reference) has been included in the Discussion stressing the potential importance of this approach in detecting molecular intratumoural heterogeneity.

To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.

Introduction

Clear cell renal cell carcinoma (CCRCC) is the most frequent form of renal cancer in Western Countries1 and a paradigmatic example of intratumoural heterogeneity (ITH)25. ITH is a major factor in the unpredictable clinical behavior and treatment failure response that these tumors can display5 and as a consequence, detection of ITH by pathologists is becoming an increasingly important metric of clinical practice.

We have recently demonstrated that a multi-site tumor sampling (MSTS) protocol following the divide-and-conquer (DAC) algorithm outperforms routine sampling protocols (RS) in detecting ITH when tested in silico6. DAC is a well-known strategy in computer science to solve many different practical problems and consists in recursively breaking down a given problem into simpler parts (divide) until they are simple enough to be efficiently solved (conquer). Then, partial solutions are combined to solve the original problem. Since such a strategy does not necessarily increase the cost of procedures and can be performed without significant changes in the pathologist’s routine, we proposed its generalized implementation in pathology labs6,7. This study extends this hypothesis to a real life scenario by comparing the MSTS protocol with RS when detecting classic morphological ITH in a series of 38 CCRCC.

Material and methods

Thirty-eight CCRCC were prospectively collected from the Pathology Department of the Cruces University Hospital (Barakaldo, Spain). All patients were informed about the potential use for research of their surgically resected tissues, and accepted this eventuality by signing an information consent approved by the local Ethics Committee (CEIC). The two sampling protocols MSTS and RS were applied in each case. The RS8 method consisted of selecting one tissue fragment per centimeter of tumor diameter plus an additional fragment of each suspicious area by the naked eye. Alternatively, the MSTS6,7 method consisted of selecting a large number of small fragments including six to eight of them in the same cassette and fixing the number of cassettes to one per centimeter of tumor (Figure 1). Thus, the two sampling protocols made use of the same number of cassettes and, consequently, the total surface of tumor tissue selected for analysis is equivalent (restricted by the cassette dimensions). Tissue samples were fixed in formalin and embedded in paraffin following routine methods. Four-micron-thick histological slides were processed in an automatized stainer (Symphony system, Ventana Medical Systems Inc., Tucson, USA).

e912cc72-7349-4f73-b2c2-16cf9b44a40f_figure1.gif

Figure 1. Example of multi-site tumor sampling (MSTS) following the divide and conquer (DAC) strategy.

The study was performed on hematoxylin-eosin (HE) stained histological slides exclusively. Two experienced pathologists (RG, JIL) reviewed all HE sections in a blind fashion. Fuhrman grade, cell type (clear vs. granular eosinophilic), and the presence of necrosis and/or sarcomatoid change were evaluated in all cases and in both sampling methods. Grade was grouped as low (G1/2) and high (G3/4) for higher consistency. The four histological parameters were considered if they were present in the sample, no matter they were focally or extensively found in RS or affecting one or more fragments in MSTS, since the final goal was “its detection”.

Statistical analysis

Results of the two methods (RS and MSTS) were compared by applying a chi-squared test (χ2), a test applied to sets of categorical data to evaluate the hypothesis of independence between the two groups. In particular, we made use of the script chi2test.m (available to download at http://es.mathworks.com/matlabcentral/fileexchange/16177-chi2test) and run it in Matlab (The Mathworks, Inc, version 2012a). For instance, to test if MSTS detected more high-grade tumors (G3/4) than RS (results in columns H and D respectively from the Excel file containing the raw data), we first counted the total number of high labels in RS (column D) and in MSTS (column H), giving a total number of 21 cases for RS and 31 cases for MSTS. Next, considering a total number of 38 CCRCC cases, we run in Matlab p=chi2test ([31 38-31; 21 38-21]), which returns a p-value of p=0.0136. Similarly, we compare the performances of the two methods with regard to the categories of presence of granular eosinophilic cells, sarcomatoid phenotype and tumor necrosis.

Results

The series consisted of 32 males and 6 females with an average age of 63 years (range 41–87), and average tumor diameter of 8.5 cm (range 4–15). Overall, MSTS was more informative than RS in 28 of 38 cases (73.5%). In particular, MSTS detected a significantly higher number of high-grade tumors (G3/4) than RS (31 vs. 21 cases respectively, χ2 test, p=0.0136) and a significantly higher number of tumors containing granular eosinophilic cells (32 vs. 22 cases respectively, χ2 test, p=0.0114) (Table 1).

Although MSTS also detected a higher number of tumors displaying sarcomatoid phenotype (12 vs. 6 cases, respectively) and a higher number of cases presenting tumor necrosis (10 vs. 7 cases, respectively), their figures did not reach significant levels (Table 1) probably because both were detected by the naked eye and were sampled in both protocols.

Table 1. Comparison between both sampling protocols showing that MSTS outperforms RS

Histological parametersMSTSRSp value
2 test)
High grade (G3/4)31210.0136
Granular eosinophilic cells32220.0114
Sarcomatoid phenotype1260.1
Tumor necrosis1070.5

[[i] MSTS: Multi-site tumor sampling, RS: Routine sampling]

Moreover, MSTS detected a clear cell papillary renal cell carcinoma (CK7+/CD10-) component in one case that RS missed.

Dataset 1.Clinic-pathological data corresponding to the two RS and MSTS sampling methods in 38 CCRCC.
Table with the raw data analyzed in the study. The vertical axis shows the cases included in the study (1 to 38). The horizontal axis shows the clinic-pathological parameters analyzed, as follows: A: sex, B: age (years), C. tumour diameter (in centimeters), D to G: Results obtained in the RS protocol (D: tumour grade, E: presence of eosinophilic cells, F: presence of necrosis, and G: presence of sarcomatoid change), H to K: Results obtained in the MSTS protocol (H: tumour grade, I: presence of eosinophilic cells, J: presence of tumour necrosis, and K: presence of sarcomatoid change). A Chi-squared test χ2 was performed between the results obtained in the following paired rows (D and H, E and I, F and J, and G and K) to compare RS and MSTS protocols.

Discussion

The clinical importance of detecting ITH is becoming clearer as time passes and as a consequence represents one of the most challenging tasks facing pathologists today5. However, pathologists have not yet adapted the old sampling protocols and seem not aware of a concerning paradox: The success of sophisticated devices and expensive platforms in detecting key tumor mutations depends on the selection rightness of tumor pieces which are (very often) made by residents. The combination of lack of solid evidence for the necessity to change current practice and a reluctance to incur new costs and increased work load may be responsible of this attitude.

We present evidence that the MSTS protocol is much more effective than RS in detecting high grade areas and other histological parameters that determine tumor aggressiveness and prognosis in CCRCC. Importantly the MSTS protocol does not incur extra costs to pathology labs6,7. A similar approach (but for a different purpose) was already reported in 1990 by Battifora and Mehta to optimize the screening of new histologic reagents9.

A thorough histological analysis such as MSTS performs may also help the pathologists in detecting hidden or unexpected tumor histologies, i.e., hybrid tumors, collision neoplasms, histologically complex tumors, and minor but crucial components in a huge tumor, giving definite clues for a complete diagnosis.

However, the final objective of MSTS is to ensure the detection of the complete spectrum of molecular changes across each tumor as this achievement will open new possibilities for more efficient treatments, thus accomplishing oncologists expectancies10. Exhaustive molecular analyses of renal carcinomas are being performed nowadays4,5, but these approaches are difficult to be implemented in the routine practice for most of the hospitals due to their high costs. In this sense, MSTS could be regarded as an affordable alternative for a generalized application since it takes into account as a necessary premise the sustainability of health systems.

Data availability

F1000Research: Dataset 1. Clinic-pathological data corresponding to the two RS and MSTS sampling methods in 38 CCRCC, 10.5256/f1000research.9419.d13584711

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 17 Aug 2016
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Guarch R, Cortés JM, Lawrie CH and López JI. Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC) [version 2; peer review: 5 approved] F1000Research 2016, 5:2020 (https://doi.org/10.12688/f1000research.9419.2)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 17 Aug 2016
Views
11
Cite
Reviewer Report 02 Sep 2016
Giuseppe Zamboni, Department of Pathology, University of Verona, Verona, Italy 
Enrico Munari, Ospedale Sacro Cuore Don Calabria, Negrar, Italy 
Approved
VIEWS 11
This is a very interesting work in which the authors applied a simple yet very smart approach to address the very complex issue of intratumoral heterogeneity, for which clear cell renal cell carcinoma stands as a paradigm.

... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Zamboni G and Munari E. Reviewer Report For: Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC) [version 2; peer review: 5 approved]. F1000Research 2016, 5:2020 (https://doi.org/10.5256/f1000research.10144.r15895)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
11
Cite
Reviewer Report 01 Sep 2016
Kevin O. Leslie, Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, USA 
Approved
VIEWS 11
This well-designed study details a successful tissue sampling technique for addressing the inherent problem of morphologic diversity present in clear cell renal cell carcinoma. The title is appropriate, the design and methods are sound, and the conclusions are sensible.
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Leslie KO. Reviewer Report For: Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC) [version 2; peer review: 5 approved]. F1000Research 2016, 5:2020 (https://doi.org/10.5256/f1000research.10144.r16008)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
6
Cite
Reviewer Report 30 Aug 2016
Miguel A. Piris, Pathology Department, Hospital Marques de Valdecilla, Santander, Spain, Santander, Spain 
Approved
VIEWS 6
The authors demonstrate that multi-site tumor sampling improves the sensitivity for the detection of molecular heterogeneity in routine paraffin-embeded clear cell renal cell carcinoma samples.

Molecular heterogeneity is a relevant feature of the advanced cancer samples that determines the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Piris MA. Reviewer Report For: Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC) [version 2; peer review: 5 approved]. F1000Research 2016, 5:2020 (https://doi.org/10.5256/f1000research.10144.r15724)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
9
Cite
Reviewer Report 30 Aug 2016
Fabio F. Facchetti, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy 
Approved
VIEWS 9
The study extend previous demonstrations on the usefulness of this original sampling procedure, that might be relevant also to detect variability of molecular landscape in tumors, whatever is their origin.

Just an annotation to better understand the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Facchetti FF. Reviewer Report For: Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC) [version 2; peer review: 5 approved]. F1000Research 2016, 5:2020 (https://doi.org/10.5256/f1000research.10144.r15937)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
18
Cite
Reviewer Report 23 Aug 2016
Jason L. Hornick, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 
Approved
VIEWS 18
Excellent demonstration of the benefits of the proposed sampling approach. Obviously a major goal of such an approach would be to reveal molecular heterogeneity that might be missed by routine sampling. The authors might briefly comment on this in the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Hornick JL. Reviewer Report For: Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC) [version 2; peer review: 5 approved]. F1000Research 2016, 5:2020 (https://doi.org/10.5256/f1000research.10144.r15825)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 17 Aug 2016
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.